Company Overview and News

Andhra Petrochemicals announces appointment of nominee director

2017-08-05 indiainfoline
Raymond is an integrated manufacturer of worsted fabric and enjoys 60% market share in India. Branded textiles contribute 48% to ...

Company News

2017-01-10 thehindubusinessline
Andhra Petrochemicals on Tuesday informed the exchanges that its plant at Visakhapatnam has resumed operations from January 10. The company had shut the plant on December 19 following a surge in imports and transport constraints. Shares of Andhra Petrochemicals were up 5 per cent at ₹26.35 on the NSE.

Andhra Petrochemicals plant resumes operations

2017-01-10 thehindubusinessline
Andhra Petrochemicals Ltd has informed the BSE that the company manufacturing plant at Visakhapatnam has resumed operations from January 10.

Lupin launches generic Vfend® Tablets and Vfend® Oral Suspension

2016-12-19 indiainfoline
At 2:22 PM, the S&P BSE Sensex is trading at 26429 down 60 points, while NSE Nifty is trading at 8,120 down 19...

Andhra Petro unit shut down temporarily

2016-12-19 thehindubusinessline
Andhra Petrochemicals Ltd has informed the BSE that the company is compelled to shut down the plant at Visakhapatnam temporarily from December 19, 2016.

Andhra Petro to shut down Vizag plant temporarily

2016-12-19 indiainfoline
Andhra Petrochemicals is compelled to shut-down the Plant at Visakhapatnam temporarily from December 19, 2016 due to surge in imports coupled with transportation constraints.

Andhra Petrochemicals shuts plant at Vizag

2016-06-15 thehindubusinessline
Andhra Petrochemicals Ltd has informed BSE that the company's plant at Visakhapatnam has been temporarily shut-down from June 15, 2016 due to un-remunerative realisation of the company's product Oxo-Alcohols. It attributed this to surge in imports.

Dumping duty imposed on normal butanol from EU, US, Singapore, Malaysia, S Africa 

2016-04-14 thehindubusinessline
The Finance Ministry has imposed definitive anti-dumping duty on normal butanol imports from the EU, US, Singapore, Malaysia and South Africa.

Related Articles

ACIA: Acacia Communications Analysis and Research Report

6m - Asif

Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...

AGEN: Agenus Inc Analysis and Research Report

2018-05-21 - Asif

Business Agenus is a clinical-stage immuno-oncology (“I-O”) company dedicated to becoming a leader in the discovery and development of innovative combination therapies and committed to bringing effective medicines to patients with cancer. The company's business is designed to drive success in I-O through speed, innovation, and effective combination therapies. Agenus has assembled fully integrated capabilities from novel target discovery, antibody generation, cell line development, and good manufacturing practice (“GMP”) manufacturing together with a comprehensive portfolio consisting of antibody-based therapeutics, adjuvants and cancer vaccine platforms. The company leverage its immune biology platforms to identify effective combination therapies for development and have developed productive partnerships to advance its innovation. The company believe the next generation of cancer treatment will build on clinically validated antibodies targeting CTLA-4 and PD-1 combined wi...